NanoVibronix (NanoVibronix) Interest Coverage : 0 (At Loss) (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is NanoVibronix Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. NanoVibronix's Operating Income for the three months ended in Mar. 2024 was $-0.57 Mil. NanoVibronix's Interest Expense for the three months ended in Mar. 2024 was $-0.03 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for NanoVibronix's Interest Coverage or its related term are showing as below:

NAOV's Interest Coverage is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 17.895
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NanoVibronix Interest Coverage Historical Data

The historical data trend for NanoVibronix's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NanoVibronix Interest Coverage Chart

NanoVibronix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

Get a 7-Day Free Trial

NanoVibronix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Coverage	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of NanoVibronix's Interest Coverage

For the Medical Devices subindustry, NanoVibronix's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NanoVibronix's Interest Coverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoVibronix's Interest Coverage distribution charts can be found below:

* The bar in red indicates where NanoVibronix's Interest Coverage falls into.

NanoVibronix Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NanoVibronix's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, NanoVibronix's Interest Expense was $-0.14 Mil. Its Operating Income was $-3.44 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

NanoVibronix did not have earnings to cover the interest expense.

NanoVibronix's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, NanoVibronix's Interest Expense was $-0.03 Mil. Its Operating Income was $-0.57 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.09 Mil.

NanoVibronix did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

NanoVibronix (NAS:NAOV) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

NanoVibronix Interest Coverage Related Terms

Thank you for viewing the detailed overview of NanoVibronix's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

NanoVibronix (NanoVibronix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (NAS:NAOV) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

56R0:Germany

Address

525 Executive Boulevard, Elmsford, New York, NY, USA, 10523

Website

https://www.nanovibronix.com

NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

Executives

Christopher M Fashek	director	8023 VANTAGE DR, SAN ANTONIO TX 78230
Stephen Russell Brown	officer: Chief Financial Officer	18-B NEIL COURT, OCEANSIDE NY 11572
Aurora Cassirer	director	C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Maria Schroeder	director	C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Brian M Murphy	director, officer: Chief Executive Officer	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Michael Ferguson	director	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Thomas Mika	director	TEGAL CORP, 2201 SOUTH MCDOWELL BLVD, PETALUMA CA 94954
Ira A Greenstein	director	IDT CORP, 520 BROAD STREET, NEWARK NJ 07102
Harold Jacob	director, officer: Chief Medical Officer	HAADMUR MEBUYON 26, HARNOT, JERUSALEM L3 95403
Martin M Goldstein	director	C/O NANOVIBRONIX, INC., 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
William Stern	director, officer: Chief Executive Officer	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Jona Zumeris	director, officer: VP of Technology	105 MAXESS ROAD, SUITE S124, MELVILLE NY 11747
Miriam W Kelly	10 percent owner	P.O. BOX 1443, BROOKLANDVILLE MD 21022